Sun, Dec 28, 2014, 8:18 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • leonard_yun leonard_yun Mar 16, 2012 12:02 PM Flag

    Synta vs Pharmasset

    With pipeline drying up, big pharmas are actually desperate looking for new drugs and willing to pay big as early as possible, and recent $11 billion buyout of Pharmasset's Phase II anti-HCV drug by Gilead is a good example. If you are familiar with cancer and hsp90 (a relatively new and less-known but well-validated anti-cancer target) and HCV fields, it's not difficult to find that today's Synta is more like yesterday's Pharmasset in many aspects. Yes, cancer is quite different from HCV, actually a cancer drug might get FDA approval easier and faster than a HCV one due to cancer drugs' relatively lower criteria of tolerable toxicity (lower benefit-risk bar from FDA) and potency expectation (usually a few weeks/months survival improvement than old drugs could do might be good enough to win FDA approval for many deadly cancers).

 
SNTA
2.61-0.02(-0.76%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
PG&E Corporation
NYSEFri, Dec 26, 2014 4:02 PM EST
Rice Energy Inc.
NYSEFri, Dec 26, 2014 4:02 PM EST